Comparison of the effect of indacaterol versus salmeterol in patients with chronic obstructive pulmonary disease

Comparison of the effect of indacaterol versus salmeterol in patients with chronic obstructive pulmonary disease - Comparison of the effect of indacaterol versus salmeterol in patients with chronic obstructive pulmonary disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008384

Enrollment

Registered

2012-07-10

Start date

2012-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease (COPD)

Interventions

150microgram once daily Indacaterol Other LABAs(50microgram twice daily salmeterol or 2mg transdermal tulobuterol)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients able to understand and sign the Informed Consent Form. 2. Subjects above 30 years of age with a formal diagnosis of COPD and , meeting all of the following criteria. a) FEV1/forced vital capacity <0.7 measured within 30 min of inhaling beta2 agonist. b) FEV1 < 80% of predicted value. c) Patients currently treated with tiotropium. d) Patients presenting with COPD dyspnea symptoms (mMRC =/> 1) despite treatment of tiotropium.

Exclusion criteria

Exclusion criteria: 1. Patients experienced acute exacerbation within 8 weeks before the start of this study. 2. Patients with an unstable cardiac diseases. 3. Patients deemed as inappropriate for this study by investigators.

Design outcomes

Primary

Measure	Time frame
The effects of indacaterol on FEV1 compared with other LABAs in patients with COPD	—

Countries

Japan

Contacts

Public ContactMasamichi Mineshita

St. Marianna University School of Medicine Respiratory and infectious diseases

m-mine@marianna-u.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026